Patent 11879003 was granted and assigned to Kyverna Therapeutics on January, 2024 by the United States Patent and Trademark Office.
Provided herein are methods of increasing T-cell function and T-cells produced by these methods. Also provided herein are methods of treating a subject using T-cells produced by these methods.